Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis

Exclusion Criteria

• •The patient has a known hypersensitivity or contraindication to any of the following medications:
• •* Heparin
• •* Aspirin
• •* Both Clopidogrel and TIclopidine
• •* Sirolimus eluting stent
• •* Stainless steel and/or
• •* Contrast media (patients with documented sensitivity to contrast which can be effectively pre-medicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled)
• •Systemic (intravenous) Everolimus use within 12 months.
• •Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
• •Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
• •Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period